reports
- Guy Sips
- Hilde Van Boxstael
- Jacob Mekhael
- Kristof Samoy
- Livio Luyten
- Michiel Declercq
- Thibault Leneeuw
- Thomas Couvreur
- Thomas Vranken
- Wim Lewi
- Jacob Mekhael
Pharvaris Initiation: A new pill's on the way to keep the swelling at ...
Pharvaris is a Dutch biotech developing deucrictibant for HAE, a rare genetic disease with a $3bn market, in both the on-demand and prophylactic settings. We see Pharvaris as an attractive investment case underpinned by deucrictibant's de-risked B2R target, competitive phase 2 results setting it up to be the only high efficacy oral option, in addition to a validated commercial opportunity for more convenient orals as evidenced by competitor Orladeyo's successful launch despite sub-par efficacy. ...
Pharvaris Reports Fourth Quarter and Full Year 2024 Financial Results ...
Pharvaris Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update Target enrollment achieved in RAPIDe-3, a pivotal Phase 3 study of deucrictibant for the on-demand treatment of HAE attacks, strengthening confidence in clinical timelinesEnrollment underway in CHAPTER-3, a pivotal Phase 3 study of deucrictibant for prophylaxis of HAE attacks; topline data expected in 2H2026Orphan medicinal product designation granted to deucrictibant in Europe for the treatment of bradykinin-mediated angioedemaData presented at recent congresses reinforces the value of deucri...
- Dylan Shindler
- Laura Chico
Pharvaris Announces Orphan Designation Granted to Deucrictibant by the...
Pharvaris Announces Orphan Designation Granted to Deucrictibant by the European Commission ZUG, Switzerland, April 01, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced that the European Commission (EC) has granted orphan designation to its investigational drug, deucrictibant, for the treatment of bradykini...
Pharvaris Presents Long-Term Clinical Data of Deucrictibant for the Pr...
Pharvaris Presents Long-Term Clinical Data of Deucrictibant for the Prevention and Treatment of HAE Attacks at the 2025 AAAAI/WAO Joint Congress Reduced monthly HAE attack rate maintained for at least 1.5 years in CHAPTER-1 OLE study; median proportion of days with symptoms in OLE was further reduced to zero daysAll participants in CHAPTER-1 OLE who had reached week 62 reported improved health-related quality of lifeOngoing RAPIDe-2 extension study includes efficacy data from seven upper airway, including laryngeal, attacks; median time to onset of symptom relief was 0.9 hours (N=7)In both ...
Pharvaris to Participate in the Leerink Partners Global Healthcare Con...
Pharvaris to Participate in the Leerink Partners Global Healthcare Conference 2025 ZUG, Switzerland, March 03, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced that its management will participate in the Leerink Partners Global Healthcare Conference 2025, taking place from March 10-12, 2025, at the W South...
Pharvaris Outlines 2025 Strategic Priorities
Pharvaris Outlines 2025 Strategic Priorities Initiated CHAPTER-3, the pivotal Phase 3 study of deucrictibant for prophylaxis against hereditary angioedema (HAE) attacks in 2024; topline data anticipated in 2H2026Enrollment in RAPIDe-3, the pivotal Phase 3 study of deucrictibant for the on-demand treatment of HAE attacks, continuing as planned; topline data anticipated in 1Q2026Study initiation of deucrictibant for the treatment of acquired angioedema due to C1-INH deficiency (AAE-C1INH) anticipated in 2025Operating from a strong financial position with estimated cash runway into 3Q2026Compa...
- Wedbush Research
NVDA NVIDIA CORPORATION
GOOGL ALPHABET INC. CLASS A
CRM SALESFORCE.COM INC.
MDB MONGODB INC. CLASS A
AMZN AMAZON.COM INC.
AAPL APPLE INC.
IBM INTERNATIONAL BUSINESS MACHINES CORPORATION
ESTC ELASTIC N.V.
PLTR PALANTIR TECHNOLOGIES
PHVS PHARVARIS NV
SNOW SNOWFLAKE INC. CLASS A
ATXS ASTRIA THERAPEUTICS INC
- Dylan Shindler
- Laura Chico
- Dylan Shindler
- Laura Chico
Pharvaris Reports Third Quarter 2024 Financial Results and Highlights ...
Pharvaris Reports Third Quarter 2024 Financial Results and Highlights Recent Business Updates Positive long-term extension data highlighting the differentiated profile of deucrictibant for the prevention and treatment of HAE attacks presented at recent medical congressesIntend to engage in clinical development of deucrictibant for the treatment of acquired angioedema due to C1-INH deficiency (AAE-C1INH)Initiation of CHAPTER-3 global pivotal Phase 3 clinical study of deucrictibant for the prophylactic treatment of HAE using once-daily extended-release tablet expected by YE2024Operating from ...
Pharvaris to Participate in the Guggenheim Healthcare Innovation Confe...
Pharvaris to Participate in the Guggenheim Healthcare Innovation Conference ZUG, Switzerland, Nov. 12, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to prevent and treat hereditary angioedema (HAE) attacks, today announced that its management will participate in the Inaugural Guggenheim Securities Healthcare Innovation Conference, taking place from November 11-13, 2024, at the InterContinental Boston. Details are as follows: Format: Fireside ChatDate, time: Wednesday, November 13, 9:30 a.m. ET ...
Pharvaris Presents Clinical and Non-Clinical Data Supporting HAE Devel...
Pharvaris Presents Clinical and Non-Clinical Data Supporting HAE Development Program at the 2024 ACAAI Annual Scientific Meeting Data from randomized clinical studies and long-term extension studies support deucrictibant’s potential best-in-class profile, detailing its injectable-like efficacy, placebo-like tolerability, and oral convenience ZUG, Switzerland, Oct. 24, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to prevent and treat hereditary angioedema (HAE) attacks, today announced data from...
- David Nierengarten
- Dennis Pak
- Martin Fan
- Laura Chico
- David Nierengarten
- Dennis Pak
- Laura Chico
- Martin Fan
- Ritika Das
- Robert Driscoll
- Sam Ravina
Pharvaris Announces Data Highlighting Deucrictibant for the Treatment ...
Pharvaris Announces Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at Upcoming Scientific Meetings ZUG, Switzerland, Oct. 16, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to prevent and treat hereditary angioedema (HAE) attacks, today announced the acceptance of multiple abstracts at several upcoming scientific meetings. Presentation details are as follows: American College of Allergy, Asthma, & Immunology’s Annual Scientific Meeting (ACAAI), Boston, October 24-28, 2024...
Pharvaris to Host Virtual Investor Event on October 23, 2024
Pharvaris to Host Virtual Investor Event on October 23, 2024 ZUG, Switzerland, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to prevent and treat hereditary angioedema (HAE) attacks, today announced it will host a virtual investor event to discuss the unmet need in both the prophylactic and on-demand treatment of HAE attacks, the potential of deucrictibant to address to needs, and the current HAE market dynamics, on Wednesday, October 23, 2024, at 10:00 a.m. ET/16:00 CET. To regi...
Pharvaris Announces Data Highlighting Deucrictibant for the Treatment ...
Pharvaris Announces Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at the 2024 HAEi Global Leadership Workshop ZUG, Switzerland, Oct. 03, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to prevent and treat hereditary angioedema (HAE) attacks, today announced the acceptance of six abstracts, two for oral presentation and four for poster presentation, at the 2024 Global Angioedema Forum – HAEi Global Leadership Workshop, taking place in Copenhagen, Denmark, from Oct. 4-5, 20...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.